

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 8, 2006

TECHNE CORPORATION  
(Exact Name of Registrant as Specified in Charter)

Minnesota	0-17272	41-1427402
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	I.R.S. Employer Identification No.)

614 Mckinley Place NE	
Minneapolis, MN	55413
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (612) 379-8854

Not Applicable  
(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- // Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- // Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- // Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- // Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on August 8, 2006, describing the results of operations for the quarter and fiscal year ended June 30, 2006 and its financial condition as of June 30, 2006, is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and fiscal year ended June 30, 2006 which has been included on Techne Corporation's website ([www.techne-corp.com](http://www.techne-corp.com)), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated August 8, 2006.

99.2 Segment information for the quarter and fiscal year ended June 30, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 8, 2006                      TECHNE CORPORATION

By: /s/ Thomas E. Oland

-----  
Name: Thomas E. Oland  
Title: President and Chief  
Executive Officer

EXHIBIT INDEX

Exhibit No. Description

- 
- 99.1 Press release of Techne Corporation dated August 8, 2006.
  - 99.2 Segment information for Techne Corporation for the quarter and fiscal year ended June 30, 2006.

TECHNE CORPORATION RELEASES UNAUDITED FOURTH QUARTER  
RESULTS FOR FISCAL YEAR 2006

Minneapolis/August 8, 2006/--Techne Corporation's (NASDAQ: TECH) consolidated net earnings increased 10.9% to \$73.4 million and its earnings per diluted share increased 14.2% to \$1.85 compared with \$66.1 million and \$1.62 per diluted share for the fiscal year ended June 30, 2005. For the quarter ended June 30, 2006, Techne's consolidated net earnings increased 5.0% to \$19.5 million and its earnings per diluted share increased 4.3% to \$.49 for the quarter ended June 30, 2006 compared with \$18.6 million and \$.47 per diluted share for the quarter ended June 30, 2005.

Consolidated net earnings and diluted earnings per share for the periods ended June 30, 2006 were impacted by stock option related compensation expense from the adoption of Financial Accounting Standards Board (FASB) Statement of Accounting Standards No. 123 (Revised 2004), Share-Based Payments (SFAS No. 123R). Consolidated net earnings and diluted earnings per share for the fiscal year ended June 30, 2006 were also impacted by the decline in exchange rates used to convert R&D Europe results from British pound sterling to U.S. dollars. The acquisitions of Fortron Bio Science, Inc. and BiosPacific, Inc. on July 1, 2005 and an accelerated stock buyback transaction ("ASB") on March 1, 2005 had positive impacts on current year reported amounts. The impact of these items on comparable net earnings and diluted earnings per share is summarized as follows:

Periods Ended June 30, 2006						
Fourth Quarter			Fiscal Year			
Net Earnings	% of Net Sales	Diluted EPS	Net Earnings	% of Net Sales	Diluted EPS	
(\$000's)		(\$000's)				
Net earnings as reported	\$19,489	37.4%	\$0.49	\$73,351	36.2%	\$1.85
Plus stock option expense (1)	85	0.2%	--	1,145	0.6%	0.03
(Less) plus foreign exchange (1)	(17)	--	--	659	0.3%	0.02
(Less) earnings from acquisitions (1)	(129)	(0.2%)	--	(515)	(0.3%)	(0.01)
ASB		--		(0.08)		
	\$19,428	37.4%	\$0.49	\$74,640	36.8%	\$1.81
Periods ended 6/30/05	\$18,567	39.0%	\$0.47	\$66,132	37.0%	\$1.62
Change	4.6%	4.3%	12.9%		11.7%	

(1) Net of income taxes

Consolidated net sales for the three months and fiscal year ended June 30, 2006 were \$52.1 million and \$202.6 million, respectively. This was an increase of 9.5% and 13.4% from the three months and fiscal year ended June 30, 2005, respectively. R&D Systems' Biotechnology Division net sales for the three months and fiscal year ended June 30, 2006 were \$32.3 million and \$125.0 million, increases of 9.1% and 12.5%, respectively, as compared to prior-year periods. Approximately \$670,000 and \$1.3 million of the increase in Biotechnology Division net sales for the quarter and fiscal year ended June 30, 2006 was the result of price increases. R&D Europe's net sales for the three months ended June 30, 2006 were \$13.5 million, a decrease of 3.0% from the prior year, while net sales for the fiscal year ended June 30, 2006 were \$53.0 million, an increase of 3.2% as compared to the prior year. In British pound sterling, R&D Europe's net sales decreased 3.9% in the fourth quarter from the fourth quarter of the prior year, but increased 7.8% for the fiscal year ended June 30, 2006. Compared to the prior year, R&D Systems Europe had two fewer shipping days in the quarter ended June 30, 2006 due to the timing of the European Easter holiday. In addition, sales in Germany declined 12.6% in the quarter ended June 30, 2006 as compared to the same quarter last year, primarily due to a work stoppage by researchers which has since been settled. R&D Systems' Hematology Division net sales for the three months ended June 30, 2006 were \$4.2 million, an increase of 5.5% as compared to the quarter ended June 30, 2005. Hematology sales for the fiscal year

were \$15.2 million, a decrease of 5.8% from the prior fiscal year, mainly as a result of a large OEM customer changing to a new primary vendor in January 2005. Included in consolidated net sales for the three months and fiscal year ended June 30, 2006 was \$2.0 million and \$9.4 million, respectively, of net sales from Fortron Bio Science, Inc. and BiosPacific, Inc., which were acquired effective July 1, 2005.

(\$000's)	Periods Ended June 30					
	Fourth Quarter			Fiscal Year		
	2006	2005	Change	2006	2005	Change
Net sales as reported	\$52,066	\$47,551	9.5%	\$202,617	\$178,652	13.4%
Less foreign exchange	(86)		(0.2%)	2,440		1.3%
Less acquisitions	(2,019)		(4.2%)	(9,351)		(5.2%)
	\$49,961	\$47,551	5.1%	\$195,706	\$178,652	9.5%

Consolidated gross margins were 77.3% and 77.4% for the quarter and fiscal year ended June 30, 2006, respectively. Excluding Fortron and BiosPacific, gross margins for the quarter ended June 30, 2006 were 78.9% compared to 79.3% in the fourth quarter of fiscal 2005, and 79.5% for the fiscal year ended June 30, 2006 compared to 79.4% for the fiscal year ended June 30, 2005. Combined gross margins for Fortron and BiosPacific operations of 38.7% and 34.4% for the quarter and fiscal year ended June 30, 2006, respectively, were affected by inventory on hand at the acquisition date that was recorded at fair value as determined by purchase accounting.

Selling, general and administrative expenses increased \$3.1 million for the fiscal year ended June 30, 2006 primarily due to \$1.6 million of stock option expense from the adoption of SFAS No. 123R in fiscal 2006. Excluding the impact of adopting SFAS No. 123R, selling, general and administrative expense as a percent of net sales decreased to 12.8% from 13.7% for the fiscal years ended June 30, 2006 and 2005, respectively.

The dollar increases in selling, general and administrative expenses were also impacted by the acquisitions of Fortron and BiosPacific.

(\$000's)	Periods Ended June 30					
	Fourth Quarter			Fiscal Year		
	2006	2005	Change	2006	2005	Change
S,G&A as reported	\$6,269	\$6,173	1.5%	\$27,604	\$24,476	12.8%
Less stock option expense	(112)		(1.8%)	(1,628)		(6.7%)
Less acquisitions	(279)		(4.5%)	(1,255)		(5.1%)
	\$5,878	\$6,173	(4.8%)	\$24,721	\$24,476	1.0%

The Company allocated approximately \$12.8 million to goodwill and \$7.1 million to other intangible assets arising from the acquisition of Fortron and BiosPacific. The intangible assets, mainly technologies, trade names and customer and supplier relationships, are being amortized over lives of one to eight years and amortization expense of \$271,000 and \$1,086,000 was recorded for the quarter and fiscal year ended June 30, 2006, respectively, related to these assets.

In April 2006, the Company made an additional \$9 million investment in ChemoCentryx, Inc. (CCX) in the form of a convertible note subject to the limitation that the Company's holdings in CCX will not exceed 19.9% of CCX voting shares. In June 2006, approximately \$4.3 million of the note was converted into shares of CCX preferred stock. The Company currently holds a 19.9% interest in CCX.

#### Forward Looking Statements:

This earnings release contains forward-looking statements within the meaning of the Private Litigation Reform Act. These statements risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future,

could affect the Company's actual results: the integration of the recent acquisitions, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in this release due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

Use of Non-GAAP Financial Measures:

The non-GAAP financial measures used in this press release quantify the impact of adopting Financial Accounting Standards Board (FASB) Statement of Accounting Standards No. 123 (Revised 2004), Share-Based Payments (SFAS No. 123R) related to the expensing of stock option compensation, the decline in exchange rates used to convert R&D Europe results from British pounds to U.S. dollars, the acquisitions of Fortron Bio Science, Inc. and BiosPacific, Inc. on July 1, 2005 and an accelerated stock buyback transaction ("ASB") on March 1, 2005 on reported net sales, selling, general and administrative expenses, net earnings and earnings per share for the three months and fiscal year ended June 30, 2006 as compared to the reported amounts for the same periods ended June 30, 2005. These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. We view these non-GAAP financial measures to be helpful in assessing the Company's ongoing operating results. In addition, these non-GAAP financial measures facilitate our internal comparisons to historical operating results and comparisons to competitors' operating results. We include these non-GAAP financial measures in our earnings announcement because we believe they are useful to investors in allowing for greater transparency related to supplemental information we use in our financial and operational analysis. Investors are encouraged to review the reconciliations of the non-GAAP financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.

\* \* \* \* \*

?

Techn Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, Fortron Bio Science, Inc. (Fortron), located in Minneapolis, and BiosPacific, Inc. (BiosPacific), located in Emeryville, California. Fortron develops and manufactures antibodies and BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D Europe is a distributor of biotechnology products.

Contact: Greg Melsen, Chief Financial Officer  
 Kathy Backes, Controller  
 (612) 379-8854

TECHNE CORPORATION  
 CONSOLIDATED STATEMENTS OF EARNINGS  
 (In thousands, except per share data)  
 (Unaudited)

	QUARTER ENDED		FISCAL YEAR ENDED	
	6/30/06	6/30/05	6/30/06	6/30/05
Net sales	\$52,066	\$47,551	\$202,617	\$178,652
Cost of sales	11,822	9,847	45,718	36,813
Gross margin	40,244	37,704	156,899	141,839

Operating expenses:				
Selling, general and administrative	6,269	6,173	27,604	24,476
Research and development	4,773	4,441	18,825	18,379
Amortization of intangible assets	491	305	1,967	1,221
	-----			
Total operating expenses	11,533	10,919	48,396	44,076
	-----			
Operating income	28,711	26,785	108,503	97,763
Other expense (income):				
Interest expense	258	206	964	822
Interest income	(1,522)	(929)	(4,708)	(4,109)
Other non-operating expense (income), net	363	(42)	1,084	1,163
	-----			
Total other expense (income)	(901)	(765)	(2,660)	(2,124)
	-----			
Earnings before income taxes	29,612	27,550	111,163	99,887
Income taxes	10,123	8,983	37,812	33,755
	-----			
Net earnings	\$19,489	\$18,567	\$ 73,351	\$ 66,132
	=====			
Earnings per share:				
Basic	\$ 0.50	\$ 0.48	\$ 1.88	\$ 1.64
Diluted	\$ 0.49	\$ 0.47	\$ 1.85	\$ 1.62
Weighted average common shares outstanding:				
Basic	39,374	38,545	39,049	40,359
Diluted	39,487	39,396	39,594	40,920

TECHNE CORPORATION  
CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

6/30/06    6/30/05

ASSETS

Cash and equivalents	\$ 89,634	\$ 80,344
Short-term available-for-sale investments	19,212	16,790
Trade accounts receivable	23,769	22,041
Other receivables	1,309	1,681
Inventory	9,024	7,758
Other current assets	6,874	6,367
	-----	
Current assets	149,822	134,981
Available-for-sale investments	77,660	41,871
Property and equipment, net	88,772	89,036
Goodwill and intangible assets, net	32,021	14,138
Other non-current assets	22,237	15,237
	-----	
Total assets	\$ 370,512	\$ 295,263
	=====	

LIABILITIES

Current liabilities	\$ 17,966	\$ 14,016
Long-term debt	12,198	13,378
Stockholders' equity	340,348	267,869
	-----	
Total liabilities and equity	\$ 370,512	\$ 295,263
	=====	

SEGMENT INFORMATION  
TECHNE CORPORATION AND SUBSIDIARIES  
(in thousands of \$'s, except per share data)

<TABLE>  
<CAPTION>

	Fiscal 2006				Increase (Decrease) From Fiscal 2005						
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent YTD	Percent of Sales	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	YTD
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Sales	47,709	48,029	54,813	52,066	202,617	100%	6,790	5,782	6,878	4,515	23,965
Cost of sales	11,096	10,695	12,105	11,822	45,718	23%	2,209	1,754	2,967	1,975	8,905
Gross margin	36,613	37,334	42,708	40,244	156,899	77%	4,581	4,028	3,911	2,540	15,060
Gross margin percentage	76.7%	77.7%	77.9%	77.3%	77.4%						
SG&A expense	6,454	7,980	6,901	6,269	27,604	14%	820	1,690	522	96	3,128
R&D expense	4,717	4,574	4,761	4,773	18,825	9%	29	(45)	130	332	446
Amortization expense	492	492	492	491	1,967	1%	187	186	187	186	746
Interest expense	223	238	245	258	964	--	(22)	60	52	52	142
Interest income	(974)	(1,130)	(1,082)	(1,522)	(4,708)	(2%)	79	59	(144)	(593)	(599)
Other non- operating ex., net	211	281	229	363	1,084	--	(255)	(135)	(94)	405	(79)
	11,123	12,435	11,546	10,632	45,736	22%	838	1,815	653	478	3,784
Earnings before income taxes	25,490	24,899	31,162	29,612	111,163	55%	3,743	2,213	3,258	2,062	11,276
Income taxes	8,489	8,385	10,815	10,123	37,812	19%	934	633	1,350	1,140	4,057
	17,001	16,514	20,347	19,489	73,351	36%	2,809	1,580	1,908	922	7,219

</TABLE>

Diluted earnings per share	0.43	0.42	0.52	0.49	1.85
Weighted average diluted shares outstanding	39,669	39,761	39,425	39,487	39,594

BIOTECHNOLOGY (1)  
(in thousands of \$'s)

<TABLE>  
<CAPTION>

	Fiscal 2006				Increase (Decrease) From Fiscal 2005						
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent YTD	Percent of Sales	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	YTD
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Sales	37,599	37,697	43,013	40,076	158,385	100%	6,908	7,625	6,675	4,434	25,642
Intersegment sales	(5,299)	(6,555)	(6,396)	(5,711)	(23,961)		(495)	(1,351)	(798)	273	(2,371)
	32,300	31,142	36,617	34,365	134,424		6,413	6,274	5,877	4,707	23,271
Cost of sales	8,470	8,147	9,125	8,597	34,339	22%	2,359	2,077	2,757	1,555	8,748
Intersegment sales	(5,323)	(6,140)	(6,478)	(5,757)	(23,698)		(567)	(930)	(999)	240	(2,256)
	3,147	2,007	2,647	2,840	10,641		1,792	1,147	1,758	1,795	6,492
Gross margin	29,153	29,135	33,970	31,525	123,783	78%	4,621	5,127	4,119	2,912	16,779

Gross margin Percentage	77.5%	78.4%	78.8%	78.5%	78.3%							
SG&A expense	3,639	4,194	4,199	3,410	15,442	10%	666	779	487	(7)	1,925	
R&D expense	4,532	4,404	4,593	4,585	18,114	11%	32	(26)	161	338	505	
Amortization expense	492	492	492	491	1,967	1%	187	186	187	186	746	
Interest, net	(268)	(373)	(285)	(501)	(1,427)	(1%)	146	191	35	(222)	150	
	8,395	8,717	8,999	7,985	34,096	21%	1,031	1,130	870	295	3,326	
Pretax result	20,758	20,418	24,971	23,540	89,687	57%	3,590	3,997	3,249	2,617	13,453	

</TABLE>

(1) Fiscal 2006 includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

R&D SYSTEMS EUROPE  
(in thousands of British pound sterling)

<TABLE>

<CAPTION>

	Fiscal 2006				Increase (Decrease) From Fiscal 2005						
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent YTD	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent of Sales	YTD
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Sales	6,690	7,529	8,256	7,278	29,753	100%	610	721	1,125	(297)	2,159
Cost of sales	3,292	3,765	4,191	3,630	14,878	50%	361	632	966	8	1,967
Gross margin	3,398	3,764	4,065	3,648	14,875	50%	249	89	159	(305)	192
Gross margin percentage	50.8%	50.0%	49.2%	50.1%	50.0%						
SG&A expense	1,004	1,185	1,070	1,115	4,374	15%	54	24	48	18	144
Interest income	(326)	(329)	(342)	(369)	(1,366)	(5%)	(72)	(66)	(62)	(62)	(262)
Exchange loss/(gain)	15	26	(49)	(9)	(17)	--	(11)	70	(65)	39	33
	693	882	679	737	2,991	10%	(29)	28	(79)	(5)	(85)
Pretax result	2,705	2,882	3,386	2,911	11,884	40%	278	61	238	(300)	277

</TABLE>

R&D SYSTEMS EUROPE  
(in thousands of \$'s)

<TABLE>

<CAPTION>

	Fiscal 2006				Increase (Decrease) From Fiscal 2005						
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent YTD	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent of Sales	YTD
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Sales	11,875	13,106	14,496	13,477	52,954	100%	856	242	953	(412)	1,639
Cost of sales	5,844	6,554	7,358	6,723	26,479	50%	532	636	1,232	68	2,468
Gross margin	6,031	6,552	7,138	6,754	26,475	50%	324	(394)	(279)	(480)	(829)
Gross margin percentage	50.8%	50.0%	49.2%	50.1%	50.0%						
SG&A expense	1,782	2,059	1,879	2,064	7,784	15%	60	(135)	(60)	53	(82)
Interest income	(579)	(572)	(600)	(680)	(2,431)	(5%)	(119)	(75)	(69)	(115)	(378)
Exchange loss/(gain)	28	46	(87)	(17)	(30)	--	(19)	128	(116)	71	64



	1,231	1,533	1,192	1,367	5,323	10%	(78)	(82)	(245)	9	(396)
Pretax result	4,800	5,019	5,946	5,387	21,152	40%	402	(312)	(34)	(489)	(433)

</TABLE>

HEMATOLOGY  
(in thousands of \$'s)

<TABLE>  
<CAPTION>

	Fiscal 2006				Increase (Decrease) From Fiscal 2005						
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent YTD	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	YTD	
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>
Sales	3,534	3,781	3,700	4,224	15,239	100%	(479)	(734)	48	22	(945)
Cost of sales	2,105	2,134	2,100	2,259	8,598	56%	(115)	(29)	(23)	112	(55)
Gross margin	1,429	1,647	1,600	1,965	6,641	44%	(364)	(705)	71	108	(890)
Gross margin percentage	40.4%	43.6%	43.2%	46.5%	43.6%						
SG&A expense	384	424	441	376	1,625	11%	(25)	(12)	(64)	(82)	(183)
R&D expense	185	170	168	188	711	5%	(3)	(19)	(31)	(6)	(59)
Interest, net	(37)	(50)	(40)	(74)	(201)	(2%)	19	27	4	(36)	14
	532	544	569	490	2,135	14%	(9)	(4)	(91)	(124)	(228)
Pretax result	897	1,103	1,031	1,475	4,506	30%	(355)	(701)	162	232	(662)

</TABLE>

CORPORATE AND OTHER (2)  
(in thousands of \$'s)

<TABLE>  
<CAPTION>

	Fiscal 2006				Increase (Decrease) From Fiscal 2005						
	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Percent YTD	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	YTD	
<S>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	<C>	
Interest income	90	135	157	267	649	48	84	114	220	466	
Rental income	342	337	287	320	1,286	323	284	(31)	(40)	536	
	432	472	444	587	1,935	371	368	83	180	1,002	
SG&A expense	649	1,303	382	419	2,753	119	1,058	159	132	1,468	
Interest expense	223	238	245	258	964	59	60	52	52	223	
Other-Building expenses	443	490	520	529	1,982	79	12	(7)	197	281	
Other-Hemerus losses	82	82	83	171	418	8	9	(2)	97	112	
	1,397	2,113	1,230	1,377	6,117	265	1,139	202	478	2,084	
Pretax result	(965)	(1,641)	(786)	(790)	(4,182)	106	(771)	(119)	(298)	(1,082)	

</TABLE>

(2) Unallocated corporate expenses and Techne's share of losses by Hemerus Medical, LLC.